Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 6/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29051019 | 1.00 | CTSS (0.57) | CTSSCTSKCTSLCTSBNOD2 | |
| SCHEMBL29051015 | 1.00 | CTSS (0.57) | CTSSCTSKCTSLCTSBNOD2 | |
| SCHEMBL29051009 | 0.90 | NOD2 (0.62) | CTSSCTSKCTSLCTSBNOD2 | |
| SCHEMBL29488062 | 0.90 | NOD2 (0.62) | CTSSCTSKCTSLCTSBNOD2 | |
| SCHEMBL28269171 | 0.88 | CTSS (0.57) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL28766261 | 0.88 | CTSS (0.57) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL28269406 | 0.88 | CTSS (0.57) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL28766262 | 0.88 | CTSS (0.57) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL29651388 | 0.88 | CTSS (0.57) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL17706781 | 0.87 | PPARA (0.52) | CTSSCTSKCTSLCTSBACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | UNIVERZA V LJUBLJANI (SI) | 2023-11-30 | — | — | US | disclosed |
| EP-4232094-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | Univerza V Ljubljani (SI) | 2023-08-30 | — | — | EP | disclosed |
| CN-116600830-A | Conjugated TLR7 and NOD2 agonists | 卢布尔雅那大学 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022084417-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | UNIVERZA V LJUBLJANI (SI) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | NOD2, TLR7, TLR9 | CTSS 2890/4885CTSK 2307/4885CTSL 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.